NCT06334393View on ClinicalTrials.gov

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

April 21, 2025

Study Completion Date

April 27, 2026

Conditions

ZikaZika Virus Infection

Interventions

BIOLOGICAL

VLA1601

0.45mL (milliliter), Day 1 and 29

BIOLOGICAL

CpG 1018®

CpG 1018® will be investigated in combination with VLA1601 Low dose

BIOLOGICAL

3M-052-AF

3M-052-AF will be investigated in combination with VLA1601 Low dose

Trial Locations (4)

51106

Velocity Clinical Research, Sioux City

60640

Flourish Research, Chicago

68134

Velocity Clinical Research, Omaha

68510

Velocity Clinical Research, Lincoln

All Listed Sponsors

lead

Valneva Austria GmbH

INDUSTRY

NCT06334393 - Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults | Biotech Hunter | Biotech Hunter